Market Analysis - Annual Clinical Microbiology
The Global Clinical Microbiology Market is projected to reach USD 5.77 Billion by 2021 from USD 3.35 billion in 2016, at a CAGR of 11.5%, during the duration 2016 to 2021. On the basis of product, the Clinical Microbiology market is categorized into gram strainers, bacterial colony counters, incubators, autoclave sterilizers, anaerobic culture systems, microbial air samplers, petri dish fillers, blood culture systems, microbial culture systems which come under laboratory instruments and other laboratory instruments and such as microscopes, molecular diagnostic instruments, and mass spectrometers and reagents like pathogen specific kits and general reagents which are categorized as microbiology analyzers. The instruments sector is expected to account for the larger share of the Global Clinical Microbiology market than the reagents sector in 2016. However, reagents sector is predicted to grow faster than the instruments sector, growing at a double-digit CAGR during 2016–2021. Growth in the reagents sector is largely driven by growing trend of reagent rental agreements (along with instrument sales) by prominent reagent manufacturers, raising private-public funding for researches on specific infectious diseases, increasing market obtainability of pathogen-specific kits across the globe, and growing demand for specific Clinical Microbiology reagents during widespread epidemic outbreaks.
• Microbiological Testing/Clinical Microbiology product manufacturers
• Healthcare service providers (Including hospitals and diagnostic centers)
• Food and beverages manufacturing companies
• Petrochemical and biofuel product manufacturing companies
• Oil & gas producing and distribution companies
• Pharmaceutical product manufacturing companies
• Clinical testing laboratories
• Clinical Research Organizations (CROs)
• Gas operators, distributors, and regulators
• Market research and consulting firms
• Environmental monitoring committees
• Environmental monitoring product manufacturing companies
• Research laboratories and academic institutes
Leading players in the clinical microbiology market include:
• BioMerieux S.A. (France),
• Danaher Corporation (U.S.)
• Becton, Dickinson and Company (U.S.)
• Cepheid (U.S.)
• Abbott Laboratories Inc. (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• F.Hoffman-La Roche Ltd. (Switzerland)
• Alere Inc. (U.S.), Bruker Corporation (U.S.)
• Hologic, Inc. (U.S.)
The global market for selected HAI treatments was nearly $19.8 billion in 2017 with a compound annual growth rate (CAGR) of 8.2%. This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. This report provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
Clinical Microbiology market in Laboratory Instruments and Reagents:
The global market for life science tools and reagents reached and $67.6 billion in 2017, with a projected five-year compound annual growth rate (CAGR) of 8.6%. The scope of this study encompasses tools and reagents in the life sciences for pharmaceutical and biotechnology markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for life science tools and reagents includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, etc
Bacterial colony counters
Microbial air samplers
Anaerobic culture systems
Blood culture systems
Microbial culture systems
Other laboratory instruments
Molecular diagnostic instruments
Pathogen specific kits
Global Microbiology Market:
Microbial life is amazingly diverse and microorganisms literally cover the planet. It is estimated that we know less than 1% of the microbial species on Earth. Molecular biology has revolutionized the study of microorganisms in the environment and improved our understanding of the composition, phylogeny, and physiology of microbial communities. The current molecular toolbox encompasses a range of DNA-based technologies and new methods for the study of RNA and proteins extracted from environmental samples.
Owing to the clinical and medical market, it is expected to reach USD 5.77 billion by the year 2021 from USD 3.35 billion, growing at CAGR value of 11.5%. With the advent of new technologies and innovations, for instance, PCR, the driving force behind the growth of the microbial diagnostic market. With the automation in the technologies in the clinical diagnostics, the traditional clinical microbiology diagnostics has seen a drastic fall, due to the reduction in the labor, time, chemicals, and other cost pressures. The highly rising molecular diagnostics market is expected to reach USD 9,333.8 Million by 2021.
The advent of vaccines to prevent deadly childhood illnesses was one of the great success stories of the 20th century. Recent advances in vaccine technology stemming from the application of genetic engineering are now providing an opportunity to target new diseases. The previous century’s successes in reducing the primary causes of mortality in childhood now include protecting against infectious agents that can result in significant morbidity. Scientific progress and these broadened applications will no doubt result in improved health-based outcomes, but progress often comes at a significant short-term cost. Although it is true that improved outcomes are the goal of health care technology and that preventing disease is preferable to treatment, thus reducing overall costs, confusion persists about the best course going forward. Geographically, the vaccines market is dominated by North America, followed by Europe, Asia, and the Rest of the World. Growth in the North American segment is primarily driven by government initiatives for immunization against diseases such as influenza and HPV in the North American countries.
After the success of Clinical Microbiology 2012- 2017, Conferenceseries is glad to announce 8th Annual Congress on Clinical Microbiology (Clinical Microbiology-2018) during December 05-06, 2018 Toronto, Ontario, Canada.
Conferenceseries organises 300 International Conferences Every Year across globe with support from 1000 more scientific societies and Publishes 500+ Open access journals which contains over 50000 eminent personalities, 50,000 reputed scientists as editorial board members and 5 million readers.
This meeting will focus in particular on the current research on the laboratory diagnosis of infections and outbreaks, and the primary role of the laboratory in the management of infectious disease outbreaks and the epidemiology of infections.
Why to attend?
- Best platform to develop new partnership & collaborations.
- Best location to speed up your route into every territory in the World.
- 89% our conference attendees are the Key contact in their labs purchasing decisions.
- Our exhibitor booths were visited 4-5 times by 80% of the attendees during the conference.
- Past exhibitor’s feedback reveals ample of enquiries perceived from the conference attendees.
- Network development with both Academia and Business.
We invite experts in the field of clinical microbiology including bacteriologist, virologist, molecular microbiologist, infection and quality control clinicians, exercise physicians, yoga practitioners, veterinary microbiologist and delegates from industries focusing on microbiology, molecular genomics and industrialist involved in biomedical research as well.